
Acurex Biosciences
Biotechnology, San Carlos, California, 94039, United States, 11-50 Employees
Phone Number: +19*********
Who is ACUREX BIOSCIENCES
Acurex Biosciences is a pharmaceutical company with a mission to halt major neurodegenerative diseases driven by impaired mitophagy, starting with Parkinsons disease (PD). A large body of...
Read More

-
Headquarters: San Carlos, California, 94039, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 6531
Does something look wrong? Fix it. | View contact records from ACUREX BIOSCIENCES
Acurex Biosciences Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Acurex Biosciences
Answer: Acurex Biosciences's headquarters are located at San Carlos, California, 94039, United States
Answer: Acurex Biosciences's phone number is +19*********
Answer: Acurex Biosciences's official website is https://acurex.com
Answer: Acurex Biosciences's revenue is $1 Million to $5 Million
Answer: Acurex Biosciences's SIC: 6531
Answer: Acurex Biosciences has 11-50 employees
Answer: Acurex Biosciences is in Biotechnology
Answer: Acurex Biosciences contact info: Phone number: +19********* Website: https://acurex.com
Answer: Acurex Biosciences is a pharmaceutical company with a mission to halt major neurodegenerative diseases driven by impaired mitophagy, starting with Parkinsons disease (PD). A large body of evidence now supports that impairment of mitophagy, the normal process by which cells dispose of dysfunctional mitochondria, plays a significant role in the pathogenesis of PD and other diseases. Acurexs platform and founding intellectual property are based on a Stanford University breakthrough discovery enabling the identification of druggable targets responsible for defects in mitophagy. Acurexs platform has generated two oral small-molecule therapeutic programs that cross the BBB, reactivate mitophagy, and protect PD patient-derived neurons. Acurexs lead program will begin IND-enabling studies in 2H 2023, and the second program to a distinct target is in lead selection. Acurexs clinical development plan leverages its proprietary biomarker of mitophagy that can be measured in the periphery and is significantly altered in PD patients, including patients with LRRK2 and GBA PD. Acurexs mitophagy biomarker changes with drug treatment, enabling early efficacy insights and de-risking in phase 1b rather than in phase 2b trials. Acurex's biomarker for pre-selection and stratification of patients combined with our drug treatment will be a significant step forward in bringing personalized medicine to treating CNS diseases.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface

Sign in to CIENCE GO Data to uncover contact details
Free credits every month